1,377 Shares in The Cigna Group (NYSE:CI) Bought by Lincoln Capital Corp

Lincoln Capital Corp bought a new stake in The Cigna Group (NYSE:CI) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,377 shares of the health services provider’s stock, valued at approximately $380,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ulland Investment Advisors LLC lifted its holdings in The Cigna Group by 2,500.0% during the 3rd quarter. Ulland Investment Advisors LLC now owns 104 shares of the health services provider’s stock worth $36,000 after buying an additional 100 shares during the period. Prospera Private Wealth LLC acquired a new stake in shares of The Cigna Group during the third quarter worth $37,000. ORG Wealth Partners LLC acquired a new position in The Cigna Group in the fourth quarter valued at $34,000. Harbor Capital Advisors Inc. acquired a new stake in The Cigna Group during the 3rd quarter worth about $45,000. Finally, Intact Investment Management Inc. acquired a new stake in The Cigna Group during the 3rd quarter worth about $69,000. Institutional investors own 86.99% of the company’s stock.

Wall Street Analyst Weigh In

CI has been the subject of several recent analyst reports. StockNews.com cut The Cigna Group from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Stephens restated an “overweight” rating and issued a $410.00 target price on shares of The Cigna Group in a research note on Friday, November 1st. Royal Bank of Canada cut their price target on The Cigna Group from $384.00 to $377.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Piper Sandler reaffirmed an “overweight” rating and set a $394.00 target price (up from $392.00) on shares of The Cigna Group in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of The Cigna Group from $398.00 to $394.00 and set a “buy” rating for the company in a research note on Monday, November 4th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, The Cigna Group presently has a consensus rating of “Buy” and an average target price of $395.93.

The Cigna Group Price Performance

Shares of The Cigna Group stock opened at $294.98 on Friday. The stock has a market capitalization of $82.05 billion, a P/E ratio of 27.83, a price-to-earnings-growth ratio of 0.78 and a beta of 0.54. The business’s 50 day simple moving average is $298.30 and its two-hundred day simple moving average is $326.03. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.72 and a quick ratio of 0.72. The Cigna Group has a one year low of $262.03 and a one year high of $370.83.

The Cigna Group (NYSE:CI) last released its quarterly earnings results on Thursday, October 31st. The health services provider reported $7.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.22 by $0.29. The company had revenue of $63.70 billion during the quarter, compared to the consensus estimate of $59.58 billion. The Cigna Group had a net margin of 1.31% and a return on equity of 18.42%. The Cigna Group’s revenue was up 29.8% on a year-over-year basis. During the same period in the prior year, the firm earned $6.77 earnings per share. Analysts forecast that The Cigna Group will post 28.5 EPS for the current year.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.